Menu
Not yet recruiting NCT06899321

The Effect of Cosmetic Products on Skin Brightening

No phase Interventional Skin Brightening

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cosmetic product M68, Cosmetic product Z15, Cosmetic product R52, Cosmetic product J61.
Who it may be relevant to
Registry conditions: Skin Brightening. Basic parameters: 18 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
India
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Clinical Study to Evaluate Test Products for Skin Brightening Benefit Under Controlled UV Exposure, in a 6-week Study Design

Overview

This is a single centre, single cell, blinded study designed to evaluate the effect of 5 cosmetic products on skin brightening, skin hydration and skin barrier function of the volar forearm after controlled UV exposure as compared to baseline and a no-treatment control.

Detailed description

This is a single centre, single cell, blinded study designed to evaluate the effect of cosmetic products on skin brightening, skin hydration and skin barrier function of the volar forearm after controlled UV exposure. This study will accept 34 participants who meet the inclusion and exclusion criteria. Participants will test all 5 products and a no-treatment control, which will be applied twice daily for 6 weeks to pre-defined test sites on their volar forearms.

UV exposure will be conducted using a SOL UV solar simulator (300 - 1200nm; dose level 6 joules/cm2) at various time points during weeks 2 - 5 of the study.

Instrumental assessments of skin brightening, skin hydration and skin barrier function will be conducted at regular intervals throughout the whole study. Non-invasive samples of the stratum corneum will be collected at several timepoints during the study to evaluate biomarkers of skin brightening.

Interventions

  • Other Cosmetic product M68
    Cosmetic skin brightening product to be applied to defined test site
  • Other Cosmetic product Z15
    Cosmetic skin brightening product to be applied to defined test site
  • Other Cosmetic product R52
    Cosmetic skin brightening product to be applied to defined test site
  • Other Cosmetic product J61
    Cosmetic skin brightening product to be applied to defined test site
  • Other Cosmetic product U36
    Cosmetic skin brightening product to be applied to defined test site

Primary outcome measures

  • L* measured using CM2600D [Time frame: 0 - 6 weeks]
Secondary outcome measures (3)
  • a* measured using CM2600D [Time frame: 0 - 6 weeks]
  • Skin hydration measured using Corneometer CM825 [Time frame: 0 - 6 weeks]
  • Skin barrier function (Trans-Epidermal Water Loss [TEWL]) measured using Tewameter TM300 [Time frame: 0 - 6 weeks]

Eligibility criteria

Inclusion criteria

  • Healthy female adult participants in general good health as determined from a recent medical history.
  • Participants in the age group of 18-45 years as on the day of enrolment (both ages inclusive).
  • Participants having very little hair, no burns, no cut/abrasion; no moles/tattoo/birth marks/burn marks on the test sites/areas as identified on screening.
  • Participants with long and broad forearms.
  • Participants having skin photo-type IV and V.
  • Participants with Spectrophotometer L\* value- 45 to 55 (both values included) on the identified test sites on the volar forearm.
  • Participants having uniform skin color and no sunburn/ erythema on the test sites.
  • Participants who do not have very dry or scaly skin, uneven skin tone on their volar forearms or no other signs of significant local irritation or skin disease like psoriasis.
  • Participants who agree to refrain from using pumice stone, scrubber while bathing during the study.
  • Participants who are willing to avoid direct sun exposure to the test sites.
  • Participants who have not participated in any clinical product evaluation test within past 1 month.
  • Participants able to read and sign an appropriate informed consent form indicating her willingness to participate and agree to come for regular study visits.
  • Participants willing to abide by and comply with the study protocol.
  • Participants willing to use umbrella \& wear full covered attire if she has to go in sun.
  • Participants who are willing not to participate in any other clinical study during participation in the current study.

Exclusion criteria

  • Participants with a known history or present condition of allergic response to any sunscreen products, cosmetic products, bathing soaps, detergent powder or medicine.
  • Participants who have outdoor job, extremely physical (manual) job which could cause excessive sun exposure or sweating
  • Participants who are smokers.
  • Menopausal women.
  • Participants having active skin diseases which will interfere with the test readings.
  • Participants on oral and topical medications (e.g Steroids, anti-oxidant, antibiotics) which will compromise the study.
  • Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy.
  • Participants who are pregnant, lactating or nursing.
  • Intense sun exposure/ photo allergenicity/toxicity.
  • Chronic illness which may influence the cutaneous state.
  • Participants participating in any other cosmetic or therapeutic trial.
  • Participants with any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness that will pose a health risk due to study participation as per investigator's discretion.
  • For female participants only: be pregnant, planning pregnancy or lactating/nursing. Urine pregnancy testing (UPT) will be performed at the time of screening.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Prevention

Study locations

India · 1 center
  • MS Clinical Research Pvt Ltd — Bangalore

Identifiers

NCT: NCT06899321 · SKN-SKA-4328

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗